| Mr Wayne M Kleinman, MD | |
|
18321 Clark St, Tarzana, CA 91356-3501 | |
| (818) 708-5285 | |
| Not Available |
| Full Name | Mr Wayne M Kleinman |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 40 Years |
| Location | 18321 Clark St, Tarzana, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467473751 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | G57617 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Tarzana Medical Center | Tarzana, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pacific Valley Medical Group | 3577465368 | 96 |
News Archive
Although more than nine out of ten doctors believe it is appropriate to discuss religious or spiritual issues when a patient brings them up and three out of four encourage patients' religious beliefs and practices, only half inquire, even occasionally, about a patient's faith
An age-related decline in recovery from muscle injury can be traced to a protein that suppresses the special ability of muscle stem cells to build new muscles, according to work from a team of current and former Carnegie biologists led by Chen-Ming Fan and published in Nature Metabolism.
Details of lung cell molecular pathways that promote or inhibit tissue regeneration were reported by researchers from the Perelmen School of Medicine at the University of Pennsylvania in Cell this week. Their aim is to find new ways to treat lung disorders.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326096165 PECOS PAC ID: 8527971316 Enrollment ID: O20031107000404 |
News Archive
Although more than nine out of ten doctors believe it is appropriate to discuss religious or spiritual issues when a patient brings them up and three out of four encourage patients' religious beliefs and practices, only half inquire, even occasionally, about a patient's faith
An age-related decline in recovery from muscle injury can be traced to a protein that suppresses the special ability of muscle stem cells to build new muscles, according to work from a team of current and former Carnegie biologists led by Chen-Ming Fan and published in Nature Metabolism.
Details of lung cell molecular pathways that promote or inhibit tissue regeneration were reported by researchers from the Perelmen School of Medicine at the University of Pennsylvania in Cell this week. Their aim is to find new ways to treat lung disorders.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
| Entity Name | Pacific Valley Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851312862 PECOS PAC ID: 3577465368 Enrollment ID: O20040122000762 |
News Archive
Although more than nine out of ten doctors believe it is appropriate to discuss religious or spiritual issues when a patient brings them up and three out of four encourage patients' religious beliefs and practices, only half inquire, even occasionally, about a patient's faith
An age-related decline in recovery from muscle injury can be traced to a protein that suppresses the special ability of muscle stem cells to build new muscles, according to work from a team of current and former Carnegie biologists led by Chen-Ming Fan and published in Nature Metabolism.
Details of lung cell molecular pathways that promote or inhibit tissue regeneration were reported by researchers from the Perelmen School of Medicine at the University of Pennsylvania in Cell this week. Their aim is to find new ways to treat lung disorders.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
| Entity Name | Tarzana Anesthesia Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508897463 PECOS PAC ID: 2668512914 Enrollment ID: O20091216000556 |
News Archive
Although more than nine out of ten doctors believe it is appropriate to discuss religious or spiritual issues when a patient brings them up and three out of four encourage patients' religious beliefs and practices, only half inquire, even occasionally, about a patient's faith
An age-related decline in recovery from muscle injury can be traced to a protein that suppresses the special ability of muscle stem cells to build new muscles, according to work from a team of current and former Carnegie biologists led by Chen-Ming Fan and published in Nature Metabolism.
Details of lung cell molecular pathways that promote or inhibit tissue regeneration were reported by researchers from the Perelmen School of Medicine at the University of Pennsylvania in Cell this week. Their aim is to find new ways to treat lung disorders.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Wayne M Kleinman, MD 11999 San Vicente Blvd, #440, Los Angeles, CA 90049-5131 Ph: (310) 471-5852 | Mr Wayne M Kleinman, MD 18321 Clark St, Tarzana, CA 91356-3501 Ph: (818) 708-5285 |
News Archive
Although more than nine out of ten doctors believe it is appropriate to discuss religious or spiritual issues when a patient brings them up and three out of four encourage patients' religious beliefs and practices, only half inquire, even occasionally, about a patient's faith
An age-related decline in recovery from muscle injury can be traced to a protein that suppresses the special ability of muscle stem cells to build new muscles, according to work from a team of current and former Carnegie biologists led by Chen-Ming Fan and published in Nature Metabolism.
Details of lung cell molecular pathways that promote or inhibit tissue regeneration were reported by researchers from the Perelmen School of Medicine at the University of Pennsylvania in Cell this week. Their aim is to find new ways to treat lung disorders.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
Bakhtiar Moussazadeh, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 5620 Wilbur Ave Ste 305, Tarzana, CA 91356 Phone: 818-578-5326 Fax: 951-272-9924 | |
Mr. Nelson E Koe, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 18321 Clark St, Tarzana, CA 91356 Phone: 310-471-5852 Fax: 310-471-3958 | |
Dr. Komail Saifee, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4121 Aleman Dr, Tarzana, CA 91356 Phone: 818-342-3846 | |
Ms. Deborah A. Heaps, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 18321 Clark St, Tarzana, CA 91356 Phone: 818-708-5285 | |
David Ben Hoenig, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5525 Etiwanda Ave, Suite 217, Tarzana, CA 91356 Phone: 818-344-4100 Fax: 818-344-1043 | |
Ms. Gail S. Goldstein, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 18321 Clark St, Tarzana, CA 91356 Phone: 310-471-3958 Fax: 310-471-3958 | |
Maged S. Mikhail, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 18344 Clark Street, Suite #202, Tarzana, CA 91356 Phone: 818-654-0520 Fax: 818-654-0520 |